| Literature DB >> 26408913 |
Xuyi Yue1, Christopher Bognar1, Xiang Zhang1, Gregory G Gaehle1, Stephen M Moerlein1, Joel S Perlmutter1, Zhude Tu2.
Abstract
Automated production of a promising radiopharmaceutical (-)-(1-(8-(2-[(18)F]fluoroethoxy)-3-hydroxy-1,2,3,4-tetrahydronaphthalen-2-yl)-piperidin-4-yl)(4-fluorophenyl)methanone ([(18)F]VAT) for the vesicular acetylcholine transporter(VAChT) was achieved using a two-step procedure in a current Good Manufacturing Practices fashion. The production of [(18)F]VAT was accomplished in approximately 140 min, with radiochemical yield of ~15.0% (decay corrected), specific activity>111 GBq/µmol, radiochemical purity>99% and mass of VAT ~3.4 μg/batch (n>10). The radiopharmaceutical product meets all quality control criteria for human use, and is suitable for clinical PET studies of VAChT.Entities:
Keywords: Automation; Clinical studies; Fluorine-18; Positron emission tomography; Vesicular acetylcholine transporter
Mesh:
Substances:
Year: 2015 PMID: 26408913 PMCID: PMC4681605 DOI: 10.1016/j.apradiso.2015.09.010
Source DB: PubMed Journal: Appl Radiat Isot ISSN: 0969-8043 Impact factor: 1.513